Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT with Reflex to HIV-1 Drug Resistance by Next Generation Sequencing
Use to detect and quantify HIV-1. Use to determine HIV-1 drug resistance by DNA sequencing.
Quantitative Transcription-Mediated Amplification/Massively Parallel Sequencing
New York DOH Approval Status
Lavender (EDTA), Pink (K2EDTA), or Plasma Preparation Tube (PPT).
Separate from cells within 24 hours of collection. Transfer 4 mL plasma to an ARUP Standard Transport Tube and freeze. (Min: 2.5 mL)
Serum. Heparinized specimens.
After separation from cells: Ambient: Unacceptable; Refrigerated: 72 hours; Frozen: 3 months
|HIV-1 Qnt by NAAT Interp||Not Detected|
Refer to report
If Human Immunodeficiency Virus 1 by Quantitative NAAT result is greater than or equal to 2.70 log copies/mL, then HIV- Drug Resistance by Next Generation Sequencing will be added. Additional charges apply.
87536; if reflexed add 87900; 87901; 87906
|Component Test Code*||Component Chart Name||LOINC|
|3000868||HIV-1 Qnt by NAAT (copies/mL)||20447-9|
|3000869||HIV-1 Qnt by NAAT (log copies/mL)||29541-0|
|3000970||HIV-1 Qnt by NAAT Interp||25835-0|
- HIV genotyping for drug sensitivity testing
- HIV-1 reflex to genotyping
- HIV-1 Treatment decision
- HIV-1 viral load
- Nucleic Acid Amplification Test (NAAT)
- Viral load monitoring